View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Adare Pharmaceuticals
10 March 2011

Eurand to Discuss Strategic Decision-Making at BioEurope Spring

Steve Ellul, Eurand’s director of licensing, will discuss aspects of the company’s growth strategy during the session ‘Understanding the Drivers for Strategic Decision-Making’ at BioEurope Spring in Milan, Italy, on Monday 14 March from 9am to 10.30am local time.

The panel of industry experts will provide insight into the critical decisions encountered by growing biotech companies. Acquired by Axcan Intermediate Holdings on 11 February 2011, the acquisition is the culmination of a series of events that correlated with Eurand’s growth as it executed its strategic business plan after becoming an independent company in 1999.

Ellul will relate the decisions that enabled Eurand to evolve from a technology and manufacturing partner into a fully integrated, global specialty pharmaceutical company, with a successful IPO in 2007. In late 2009, Eurand launched ZENPEP® (pancrelipase) delayed-release capsules, its first internally developed pharmaceutical product, in the US market. The ZENPEP franchise, including its 5,000-unit dose authorized generic PANCRELIPASE™, gained approximately 20% market share in 12 months.

A leading specialty GI company

“BioEurope Spring is really the first opportunity to publicly showcase the combined company to our current and future partners,” noted Stephen Perrett, vice president of portfolio development. “We’re looking forward to the future with the new company, which has a stronger, more diversified product and technology portfolio of in-market products and pipeline candidates.”

The new entity will combine two like-minded companies with complementary gastrointestinal (GI) capabilities and with an expanded global presence to partner and commercialize our portfolio of products for out-licensing.

Now available for out-licensing: Diclomax Retard® (diclofenac sodium) delayed-release capsules

Formulated using Eurand’s Diffucaps® delayed-release technology, Diclomax Retard ER provides a once-daily dosing option of the top-prescribed NSAID, improving patient compliance and providing 24 hours of therapeutic effect.

Backed by a CPP from the UK, this successful brand name and formulation is available for out-licensing in countries worldwide. Learn more at Eurand’s website.

Pharmaceutical technologies for optimal drug delivery solutions

Eurand specializes in product development that leverages its proprietary pharmaceutical technologies. The company uses these technologies — customized drug release, tastemasking, bioavailability enhancement — to develop novel pharmaceutical and OTC products designed to provide advantages over existing products or to address unmet medical needs.

Dysphagia can affect many people throughout their lifetime and may compromise medication adherence.
For pharmaceutical manufacturers and healthcare providers, non-adherence to medication is a significant concern.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology